$5.12
-1.9%CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
CALC • NASDAQ
| CalciMedica, Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-13.7M | -34.4M | -7.8M | -35.8M | -27.5M | -37M | -28.4M | |
58K | 58K | 52K | 519K | 395K | 303K | 175K | |
0.0 | -3.3M | 0.0 | 0.0 | 1K | 0.0 | 0.0 | |
2.3M | 12M | 1.8M | 5.4M | 1.8M | 738K | 348K | |
-9.3M | 110K | -6.4M | 58K | -2.2M | -140K | 18K | |
-495K | -267K | 605K | -1.6M | -4.6M | 4.9M | -379K | |
-21.1M | -25.7M | -11.8M | -31.5M | -32.1M | -31.2M | -28.2M | |
INVESTING ACTIVITIES | |||||||
-8K | -78K | -4K | -488K | -1M | -605K | -1.5M | |
-29M | -6.1M | (0.0) | -94.6M | -61.6M | -22.5M | (0.0) | |
24.6M | 15.1M | 0.0 | 105.8M | 20.1M | 2.5M | 0.0 | |
-4.4M | (8.9M) | -4K | (10.8M) | -42.6M | -20.6M | -1.5M | |
FINANCING ACTIVITIES | |||||||
28M | 25.4M | 18K | 695K | 96.3M | 0.0 | 0.0 | |
0.0 | 0.0 | 8.5M | 0.0 | 0.0 | 0.0 | 0.0 | |
20K | -4.5M | 0.0 | 0.0 | -4.1M | 89K | 124K | |
28M | 20.9M | 8.5M | 695K | 92.2M | 54.9M | 42M | |
CASH FLOW SUMMARY | |||||||
2.4M | 4.1M | -3.3M | -20.1M | 17.5M | 3M | 12.3M | |
5.5M | 1.5M | 4.8M | 33.4M | 15.9M | 12.8M | 492K | |
7.9M | 5.5M | 1.5M | 13.4M | 33.4M | 15.9M | 12.8M | |
-21.2M | -25.8M | -11.8M | -32M | -33.1M | -31.8M | -29.7M |
CALC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | January 28, 2026 | January 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 28, 2026 | January 28, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 12, 2025 | August 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 12, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 27, 2025 | June 24, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 06, 2025 | June 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | May 14, 2025 | May 14, 2025 | 2025 |
Continue your CALC research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.